INTSIntensity Therapeutics Inc. Common stock
4.860USD+15.71%Mkt Cap: 15.87M $P/E: —3d ago
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead produc…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Intensity Therapeutics, Inc.'s Q2 2026 earnings call | ||
 Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript CEO discusses resuming trials and $30M capital needs for Phase 3 sarcoma study. | ||